The move came after months of talks in which Doctors Without Borders asked Gilead Sciences for a “limited” supply of ...
New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company ...
Galapagos (GLPG) backs Gilead’s Ouro Medicines deal, sharing $1.675B upfront and milestones, plus 20–23% royalties on gamgertamig—read more.
Gilead plans to develop Ouro’s lead drug candidate, gamgertamig, alongside a Belgian pharma company.
By Mariam Sunny March 23 (Reuters) - Gilead Sciences said on Monday it would buy privately held biotech firm Ouro Medicines ...
Gilead Sciences is paying $1.67 billion for a T-cell engager (TCE) company via a front-loaded deal that could also give new ...
Gilead Sciences plans to acquire Ouro Medicines for up to about $2.18 billion and develop the assets from the deal in a ...
Promotional materials for a handful of biologics have found their way into the FDA’s hot seat. | Promotional materials for a handful of biologics have found their way into the FDA’s hot seat.
Gilead Sciences Inc. is in advanced talks to acquire Ouro Medicines, a closely held company testing novel antibody drugs ...
Takeda is launching a restructuring, targeting nearly $1.3 billion in annual savings. Generic versions of Novo Nordisk's ...
California-based drugmaker takes advantage of surging share price to strike takeovers after a quiet couple of years ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results